Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Pulse Biosciences, Inc.NASDAQ: PLSE

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables turns positive

Q2 FY2026 accounts receivables was $43K, compared with -$7K a year earlier. Trailing-twelve-month accounts receivables was -$162K.

Context

  • Accounts receivables amounted to 78.3% of revenue in FY2025.
  • Accounts receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $43K or moves back toward the trailing-twelve-month quarterly average of -$40.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$43K-21.8% QoQ
Last fiscal yearDec 2025
-$274K-670.8% YoY
LTMJun 2026
-$162K-622.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+714.3%——
1 year-670.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(274K) USD
Year-over-year change
-670.8%

Accounts Receivables vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -622.6% is the lowest of 10, against a peer median of +37.6%.
  • Accounts receivables amounts to 13.7% of revenue for PLSE, versus a peer median of 3.8%.
PLSE Competitors
Accounts Receivables for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STAASTAAR Surgical CompanyLTM Apr 2026$42.26M USD-270.2%—14.6%
NVCRNovoCure LimitedLTM Mar 2026$29.5M USD-6.9%—4.4%
OPKOPKO Health, Inc.LTM Mar 2026$16.81M USD+27.4%-38.3%2.9%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$8.99M USD+37.6%—10.7%
BBNXBeta Bionics, Inc.LTM Mar 2026$6.73M USD+143.5%—6.1%
LFMDLifeMD, Inc.LTM Mar 2026$2.58M USD+153.0%—1.2%
IMTXImmatics N.V.LTM Mar 2026€1.5M EUR+138.9%-18.5%4.0%
PLSEPulse Biosciences, Inc.LTM Jun 2026$162K USD-622.6%—13.7%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$67K USD-104.1%—3.5%
ATAIAtai Beckley Inc.LTM Jun 2026$0 USD——0.0%
NKTRNektar TherapeuticsLTM Jun 2026$0 USD+100.0%—0.0%
Peer median (excluding PLSE) —+37.6%-28.4%3.8%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
Deferred Income Tax00000
Stock-Based Compensation14.6M5.19M7.18M13.59M21.46M
Change in Working Capital(6.2M)(3.72M)768K2.47M(5.02M)
Accounts Receivables(61K)20K109K48K(274K)
Inventory(5.82M)(2.65M)00(136K)
Accounts Payables1.16M(1.3M)263K(201K)1.13M
Other Working Capital(1.47M)221K396K2.63M(5.74M)
Other Non-Cash Items13K8.66M13K6K1.15M
Operating Cash Flow(54.1M)(47.01M)(33.04M)(36.34M)(54.12M)
Capital Expenditures(437K)(401K)(121K)(125K)(315K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments8M0000
Other Investing Activities0000(20K)
Investing Cash Flow7.56M(401K)(121K)(125K)(335K)
Debt Repayment407K65M000
Common Stock Issued56.7M14.86M16.39M59.65M17.15M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities62.51M75K(6K)50.49M0
Financing Cash Flow62.69M79.94M16.39M110.14M17.15M
Effect of Forex Changes00000
Net Change in Cash16.15M32.53M(16.77M)73.67M(37.3M)
Free Cash Flow(54.53M)(47.41M)(33.16M)(36.47M)(54.44M)

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.